PAR

PARA BIO FPO [PAR]
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.1650 -2.9%

Updated 21 Jul 2026 · Signals refresh every scan

Get alerts when PAR triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track PAR — Free

Active Signals

Bullish Signals

  • Low cash runway (2 quarters) - dilution risk
  • Very high P/S ratio (11420.0x)
  • Strong revenue growth (+51%)
  • EPS estimates revised upward (+6pts)
  • Near 52-week low (9% of range)
  • Small-cap ($20-100M)
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • Revenue growing at +51% — the top line is moving in the right direction
  • RBA hiking (-3pts)
  • Calendar: Quarterly 4C in 10d (+5pts)

Risk Signals

  • MACD crossed bearish — momentum is fading
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Long-term momentum is negative — down 39% over the past year
  • The bigger volume days are the down days — volume-weighted momentum is negative (-0.51%/day)
Ask Scout AI about PAR
"What's driving PAR today?" "How does PAR compare to peers?" "Key risks for PAR?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Application for quotation of securities - PAR
NONE Notice under Section 708A
NONE Notification regarding unquoted securities - PAR

Recent ASX Announcements

2026-07-17 Application for quotation of securities - PAR
2026-07-13 Notice under Section 708A
2026-07-13 Notification regarding unquoted securities - PAR
2026-07-13 Drawdown of Tranche 4 under the Convertible Note Facility PRICE SENSITIVE
2026-07-01 Change of Director's Interest Notice

Key Metrics

$96.5M
Market Cap
1.7M
Avg Volume
0.9x
Vol Ratio
$0.14 — $0.47
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-180.2%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 70%
LLeader vs LaggardlaggardRS: -4
IInstitutional SponsorshipweakInst: 7%
MMarket DirectionneutralNeutral

Sector: Healthcare

111 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
ECS +20.0%VHL -15.4%NTI +12.5%PIQ -11.4%OSL -10.3%
Compare:PAR vs ECSPAR vs VHLPAR vs NTI
Scout Pro — Deeper Analysis for PAR
Try Pro free for 30 days
Share this analysis

Track PAR and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required